rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Peter Evan Harwin

Director

Company insider

Files Form 4 as: Director and 10% owner, Korsana Biosciences; Director, Cogent Biosciences; Director and 10% owner, Crescent Biopharma; Director, Apogee Therapeutics; Director, Zenas BioPharma; Director and 10% owner, Jade Biosciences; Director, Viridian Therapeutics; Director and 10% owner, Spyre Therapeutics.

Every Form 4 they filed

In numbers

Trades disclosed
47
Buys
4
Sells
1
Bought
$29.7M
Sold
$133.5M
Companies
9
Companies where not an officer
9
First trade
27 Aug 2020
Last trade
9 Sep 2026
Last filed
10 Sep 2026

Companies traded

Everywhere else they filed: board seats, 10% stakes, other companies
KRSA Korsana BiosciencesDirector, 10% owner · Biotechnology · last 9 Sep 20260 buys · 0 sells
COGT Cogent BiosciencesDirector · Biotechnology · last 9 Jun 20260 buys · 0 sells
CBIO Crescent BiopharmaDirector, 10% owner · Biotechnology · last 2 Jun 20261 buy · 0 sells
Apogee TherapeuticsDirector · Biotechnology · last 22 Jan 20260 buys · 1 sell
ZBIO Zenas BioPharmaDirector · Biotechnology · last 7 Oct 20252 buys · 0 sells
JBIO Jade BiosciencesDirector, 10% owner · Biotechnology · last 29 Apr 20250 buys · 0 sells
VRDN Viridian TherapeuticsDirector · Biotechnology · last 26 Jun 20240 buys · 0 sells
SYRE Spyre TherapeuticsDirector, 10% owner · Biotechnology · last 14 May 20240 buys · 0 sells
DNTH Dianthus TherapeuticsDirector, 10% owner · Biotechnology · last 29 Sep 20231 buy · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
9 Sep 2026filed 10 Sep 2026KRSA Korsana Biosciencesoption or derivative · BiotechnologySEC FORM 4 Code A—48,445 at $0.00filing
9 Jun 2026filed 11 Jun 2026COGT Cogent Biosciencesoption or derivative · BiotechnologySEC FORM 4 Code A—17,901 at $0.00filing
9 Jun 2026filed 11 Jun 2026COGT Cogent Biosciencesoption or derivative · BiotechnologySEC FORM 4 Code A—17,901 at $0.00filing
2 Jun 2026filed 3 Jun 2026CBIO Crescent Biopharmaoption or derivative · BiotechnologySEC FORM 4 Code A—11,050 at $0.00filing
22 Jan 2026filed 22 Jan 2026Apogee TherapeuticsBiotechnologySEC FORM 4 Sold$133.5M1,750,000 at $76.30filing
4 Dec 2025filed 8 Dec 2025CBIO Crescent Biopharmaoption or derivative · BiotechnologySEC FORM 4 Code P$1.8M131,434 at $13.41filing
4 Dec 2025filed 8 Dec 2025CBIO Crescent BiopharmaBiotechnologySEC FORM 4 Bought$18.2M1,360,000 at $13.41filing
7 Oct 2025filed 9 Oct 2025ZBIO Zenas BioPharmaBiotechnologySEC FORM 4 Bought$6.0M316,219 at $19.00filing
23 Jun 2025filed 23 Jun 2025CBIO Crescent Biopharmaoption or derivative · BiotechnologySEC FORM 4 Code A—9,023 at $0.00filing
4 Jun 2025filed 5 Jun 2025COGT Cogent Biosciencesoption or derivative · BiotechnologySEC FORM 4 Code A—44,700 at $0.00filing
29 Apr 2025filed 1 May 2025JBIO Jade Biosciencesoption or derivative · BiotechnologySEC FORM 4 Code A—23,017 at $0.00filing
16 Sep 2024filed 16 Sep 2024ZBIO Zenas BioPharmaoption or derivative · BiotechnologySEC FORM 4 Code C—357,143filing
16 Sep 2024filed 16 Sep 2024ZBIO Zenas BioPharmaoption or derivative · BiotechnologySEC FORM 4 Code C—2,195,871filing
16 Sep 2024filed 16 Sep 2024ZBIO Zenas BioPharmaoption or derivative · BiotechnologySEC FORM 4 Code C—6,163,236filing
16 Sep 2024filed 16 Sep 2024ZBIO Zenas BioPharmaoption or derivative · BiotechnologySEC FORM 4 Code C—2,614,287filing
16 Sep 2024filed 16 Sep 2024ZBIO Zenas BioPharmaBiotechnologySEC FORM 4 Code C—41,130filing
16 Sep 2024filed 16 Sep 2024ZBIO Zenas BioPharmaBiotechnologySEC FORM 4 Code C—252,890filing
16 Sep 2024filed 16 Sep 2024ZBIO Zenas BioPharmaBiotechnologySEC FORM 4 Code C—709,794filing
16 Sep 2024filed 16 Sep 2024ZBIO Zenas BioPharmaBiotechnologySEC FORM 4 Code C—301,077filing
16 Sep 2024filed 16 Sep 2024ZBIO Zenas BioPharmaBiotechnologySEC FORM 4 Bought$5.1M300,000 at $17.00filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Health Care5

Buys in green, sells in red, by the company’s sector.

Related people

Karen Jean FerranteDirector · Director at Cogent Biosciences, filing Form 4 there in the last year
Jonathan McNeillPresident and COO · President and COO at Crescent Biopharma, filing Form 4 there in the last year
Richard William ScalzoChief Financial Officer · Chief Financial Officer at Crescent Biopharma, filing Form 4 there in the last year
Joshua T. BrummChief Executive Officer · Chief Executive Officer at Crescent Biopharma, filing Form 4 there in the last year
Jan PinkasChief Scientific Officer · Chief Scientific Officer at Crescent Biopharma, filing Form 4 there in the last year
Edward CarrChief Accounting Officer · Also traded DNTH in the last 90 days
Barbara Harlin BisphamOfficer · Also traded CBIO in the last 90 days
Ellie Eunkyung ImChief Medical Officer · Also traded CBIO in the last 90 days